References
- Lees A. Parkinson's disease. Practical Neurology. 2010;10(4): 240-6.
- Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5.
- Hoglinger GU, Kassubek J, Csoti I, et al Differentiation of atypical Parkinson syndromes. J Neural Transm (Vienna). 2017;124(8):997-1004.
- Hayes MT. Parkinson's Disease and Parkinsonism. Am J Med. 2019;132(7):802-7.
- Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13(3):141-78.
- Katzung B, Masters S, Trevor A. Basic & clinical pharmacology, (2012), New York: McGraw-Hill Medical; 2012. p. 75-83.
- Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17(Suppl 2):S32-44.
- Hoehn MM, Rutledge CO. Acute overdose with levodopa. Clinical and biochemical consequences. Neurology 1975;25(8):792-4.
- Sporer KA. Carbidopa-levodopa overdose. Am J Emerg Med. 1991;9(1)47-8.
- Walsh SJ, Katz KD. Antiparkinsonian Agents. In Brent J et al Eds: Critical Care Toxicology, Springer International Publishing. 2016. pp. 1-21.
- Delmas G, Rothmann C, Flesch F. Acute overdose with controlled-release levodopa-carbidopa. Clin Toxicol (Phila). 2008;46(3):274-7.
- Zanelli M, Zaneti E, Bisagni A, et al Severe acute colitis related to levodopa treatment. Pathologica. 2018;110(1):75-7.
- Vermund SH, Goldstein RG, Romano AA, Atwood SJ. Accidental bromocriptine ingestion in childhood. J Pediatr, 1984;105(5):838-40.
- Fox SH, Brotchie JM. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold? Eur J Neurosci. 2019;49(3):399-409.
- Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016;76(7):759-77.